Safety and Reproducibility of Sputum Induction in Asthmatic Subjects in a Multicenter Study
Authors:
- John V. FahyJFJohn V. Fahy
- Homer A. BousheyHBHomer A. Boushey
- Stephen C. LazarusSLStephen C. Lazarus
- Elizabeth A. MaugerEMElizabeth A. Mauger
- Reuben M. CherniackRCReuben M. Cherniack
- Vernon M. ChinchilliVCVernon M. Chinchilli
- Timothy J. CraigTCTimothy J. Craig
- Jeffrey M. DrazenJDJeffrey M. Drazen
- Jean G. FordJFJean G. Ford
- James E. FishJFJames E. Fish
- Elliot IsraelEIElliot Israel
- Monica KraftMKMonica Kraft
- 1 May 2001
- journal article
- clinical trial
- Published by Oxford University Press (OUP) in American Journal of Respiratory and Critical Care Medicine
- Vol. 163 (6) , 1470-1475
Abstract
The safety of sputum induction and the reproducibility of measurements in induced sputum in multicenter studies is unknown. We examined the safety of sputum induction in a two-visit, six-center study in 79 subjects with moderate to severe asthma (mean ± SD FEV1 71 ± 12% predicted, 67% taking inhaled corticosteroids). In addition, we compared the reproducibility of markers of inflammation in induced sputum with the reproducibility of the FEV1 and the methacholine PC20. The FEV1 decreased ⩾ 20% from the postbronchodilator baseline in 14% of all subjects and in 25% of subjects whose initial prebronchodilator baseline was 40 to 60% of predicted. All subjects responded promptly to additional albuterol treatment, and no subject developed refractory bronchoconstriction requiring treatment other than reversal of bronchospasm in the study laboratory. The reproducibility of measurements of the eosinophil percentage, eosinophil cationic protein, tryptase, and methacholine PC20 were similar (concordance correlation coefficients of 0.74, 0.81, 0.79, and 0.74, respectively), without any significant among-center effect. We conclude that sputum induction can be performed safely in subjects with moderate to severe asthma in multicenter clinical trials when carried out under carefully monitored conditions. Importantly, we demonstrate that measurement of markers of inflammation in induced sputum is as reproducible as methacholine PC20 and should prove useful in the assessment of airway inflammation in multicenter clinical trials.Keywords
This publication has 17 references indexed in Scilit:
- Montelukast reduces airway eosinophilic inflammation in asthma: a randomized, controlled trialEuropean Respiratory Journal, 1999
- Induced sputum in adolescents with severe stable asthma. Safety and the relationship of cell counts and eosinophil cationic protein to clinical severityEuropean Respiratory Journal, 1999
- Prednisone-dependent asthma: inflammatory indices in induced sputumEuropean Respiratory Journal, 1999
- Sputum Induction as a Method of Analyzing Pulmonary Cells: Reproducibility and AcceptabilityJournal of Asthma, 1999
- Induced sputum to assess airway inflammation: a study of reproducibilityClinical & Experimental Allergy, 1997
- Safety of One Method of Sputum Induction in Asthmatic SubjectsAmerican Journal of Respiratory and Critical Care Medicine, 1997
- Comparison of two methods of collecting induced sputum in asthmatic subjectsEuropean Respiratory Journal, 1996
- Comparison of Regularly Scheduled with As-Needed Use of Albuterol in Mild AsthmaNew England Journal of Medicine, 1996
- Indices of Airway Inflammation in Induced Sputum: Reproducibility and Validity of Cell and Fluid-Phase MeasurementsAmerican Journal of Respiratory and Critical Care Medicine, 1996
- Differences in Interleukin-8 and Tumor Necrosis Factor-Alpha in Induced Sputum From Patients With Chronic Obstructive Pulmonary Disease or AsthmaAmerican Journal of Respiratory and Critical Care Medicine, 1996